BioCentury
ARTICLE | Clinical News

Allovectin velimogene aliplasmid: Additional Phase III data

December 9, 2013 8:00 AM UTC

Additional data from the single-blind, international Phase III AIMM trial in 390 chemotherapy-naïve patients with recurrent stage III or IV metastatic melanoma showed that 2 mg intralesional Allovecti...